| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 1.29B | — |
| Operating expense | — | — |
| Net income | 164.49M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, DUL.F returned -49.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -40.1% |
| 1 year | -49.5% |
| 5 years | +17.8% |
| 10 years | +225.0% |
| All-time high | €392.60 (Oct 2025) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in DUL.F would be worth today ›No. Alnylam Pharmaceuticals, Inc. has not paid a dividend in the past 12 months.
Alnylam Pharmaceuticals, Inc. is part of the Healthcare sector.
Alnylam Pharmaceuticals, Inc. has a market cap of 27.10B EUR, based on the latest quote.
Alnylam Pharmaceuticals, Inc. is expected to report earnings around Oct 29, 2026. That date is an estimate and has not been confirmed by the company.
